REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky

Ryan Crowe Regeneron securities defendant liability allegations focus on investor-facing statements about the Phase III Fianlimab-Libtayo Study before REGN shares declined $102.09 per share from the Class Period high. NEW YORK, Aug. 5, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies...